All In Biotech

Drug Trial Radar · NCT07816666

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Sep 24, 2026

Primary completion

Sep 29, 2028

Study completion Oct 30, 2031

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT); Ventana Medical Systems, Inc
First posted
Sep 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

Conditions

  • Platinum-sensitive Relapsed Epithelial Ovarian Cancer
  • Platinum-sensitive Relapsed Fallopian Tube Cancer
  • Platinum-sensitive Relapsed Primary Peritoneal Cancer

Interventions

  • Torvutatug samrotecanDrug

    FRa targeting antibody drug conjugate Topoisomerase I inhibitor

  • BevacizumabDrug

    Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 5 years

Locations

124 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Anchorage, Alaska · Not yet recruiting

  • Research Site

    Miami, Florida · Not yet recruiting

  • Research Site

    Indianapolis, Indiana · Not yet recruiting

  • Research Site

    Shreveport, Louisiana · Not yet recruiting

  • Research Site

    Columbia, Maryland · Not yet recruiting

  • Research Site

    Ann Arbor, Michigan · Not yet recruiting

  • Research Site

    Detroit, Michigan · Not yet recruiting

  • Research Site

    Albany, New York · Not yet recruiting

  • Research Site

    Bay Shore, New York · Withdrawn

  • Research Site

    Buffalo, New York · Not yet recruiting

  • Research Site

    Greenlawn, New York · Withdrawn

  • Research Site

    New Hyde Park, New York · Withdrawn

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    Rego Park, New York · Withdrawn

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Columbus, Ohio · Withdrawn

  • Research Site

    Mayfield Heights, Ohio · Not yet recruiting

  • Research Site

    Oklahoma City, Oklahoma · Withdrawn

  • Research Site

    Philadelphia, Pennsylvania · Not yet recruiting

  • Research Site

    Willow Grove, Pennsylvania · Not yet recruiting

  • Research Site

    Houston, Texas · Not yet recruiting

  • Research Site

    Salt Lake City, Utah · Not yet recruiting

  • Research Site

    Norfolk, Virginia · Not yet recruiting

  • Research Site

    Morgantown, West Virginia · Not yet recruiting

  • Research Site

    Auchenflower, Australia · Not yet recruiting

  • Research Site

    Blacktown, Australia · Not yet recruiting

  • Research Site

    Clayton, Australia · Not yet recruiting

  • Research Site

    Liverpool, Australia · Not yet recruiting

  • Research Site

    Porto Alegre, Brazil · Not yet recruiting

  • Research Site

    São Caetano do Sul, Brazil · Not yet recruiting

  • Research Site

    São José do Rio Preto, Brazil · Not yet recruiting

  • Research Site

    São José dos Campos, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    Teresina, Brazil · Not yet recruiting

  • Research Site

    Vitória, Brazil · Not yet recruiting

  • Research Site

    Abbotsford British Columbia, British Columbia, Canada · Not yet recruiting

  • Research Site

    Montreal, Quebec, Canada · Not yet recruiting

  • Research Site

    Montreal, Quebec, Canada · Not yet recruiting

Showing 40 of 124 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.